ERBB2 and breast carcinoma: Membrane-permeable payloads can diffuse into neighboring tumor cells with low or heterogeneous antigen expression, thereby extending efficacy beyond antigen-high populations and allowing activity, for example, in HER2-low breast cancer [10].